摘要:
This invention relates to the field of pharmaceutical chemistry and, more specifically, to pharmaceutical formulations as well as to intermediates used to prepare such formulations and to methods for manufacturing such formulations.
摘要:
This invention relates to the field of pharmaceutical chemistry and, more specifically, to pharmaceutical formulations as well as to intermediates used to prepare such formulations and to methods for manufacturing such formulations.
摘要:
Methods of treating gout flares comprising administering a composition comprising a first urate-lowering agent are disclosed. In some aspects, the first urate-lowering agent is (−)-halofenate, (−)-halofenic acid, or a pharmaceutically acceptable salt thereof. Other aspects provide for methods of reducing the number, duration, frequency or intensity of gout flares experienced by a subject.
摘要:
The present application discloses a method of lowering serum uric acid level in a subject with impaired renal function, comprising administering to the subject a compound of Formula (I), as disclosed herein.
摘要:
Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (−)-halofenate, (−)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof.
摘要:
Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (−)-halofenate, (−)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof.
摘要:
A pattern implementation technique in which a pattern is defined as a software artifact that comprises a pattern signature representing one or more parameters of the pattern and a pattern implementation model representing one or more methods for expanding the pattern in a selected software context by assigning one or more arguments to the one or more parameters.
摘要:
A pattern implementation technique in which a pattern is defined as a software artifact that comprises a pattern signature representing one or more parameters of the pattern and a pattern implementation model representing one or more methods for expanding the pattern in a selected software context by assigning one or more arguments to the one or more parameters. The pattern implementation model can be based on one or more framework code sets, each of which supports the creation of plural patterns by providing a pattern implementation model for a particular software context. The framework code sets can be rendered extensible by a pattern author by virtue of providing methods whose code is adapted to be modified by a pattern author when defining a pattern. The pattern can be applied by creating an instance of the pattern in a software context and presenting a graphical representation of the pattern instance that can be manipulated by the pattern user in order to apply arguments to the pattern parameters.
摘要:
A pattern implementation technique in which a pattern is defined as a software artifact that comprises a pattern signature representing one or more parameters of the pattern and a pattern implementation model representing one or more methods for expanding the pattern in a selected software context by assigning one or more arguments to the one or more parameters.